IP Verse

Combination Therapy - EP3461484

The patent EP3461484 was granted to Aerie Pharmaceuticals on Jun 9, 2021. The application was originally filed on Mar 14, 2014 under application number EP18206195A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3461484

AERIE PHARMACEUTICALS
Application Number
EP18206195A
Filing Date
Mar 14, 2014
Status
Granted And Under Opposition
Oct 16, 2020
Publication Date
Jun 9, 2021
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

DF MP DORRIES FRANK MOLNIA & POHLMAN PATENTANWALTE RECHTSANWALTE PARG MBBAug 18, 2021GREINER -
ISARPATENT PATENT UND RECHTSANWALTE BARTH CHARLES HASSA PECKMANN UND PARTNER MBBAug 18, 2021ISARPATENT -
ALFRED E TIEFENBACHERAug 13, 2021HAMM & WITTKOPPADMISSIBLE

Patent Citations (47) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS2009186917
DESCRIPTIONUS5770759
DESCRIPTIONUS5889052
DESCRIPTIONUS5977173
DESCRIPTIONUS5994397
DESCRIPTIONUS6025392
DESCRIPTIONUS6030999
DESCRIPTIONUS6037364
DESCRIPTIONUS6037368
DESCRIPTIONUS6048895
DESCRIPTIONWO0003736
DESCRIPTIONWO0003980
DESCRIPTIONWO9519964
DESCRIPTIONWO9610407
DESCRIPTIONWO9723223
DESCRIPTIONWO9812175
DESCRIPTIONWO9820880
DESCRIPTIONWO9820881
DESCRIPTIONWO9821180
DESCRIPTIONWO9821181
DESCRIPTIONWO9821182
DESCRIPTIONWO9839293
DESCRIPTIONWO9850024
DESCRIPTIONWO9857930
DESCRIPTIONWO9857942
DESCRIPTIONWO9902165
DESCRIPTIONWO9912895
DESCRIPTIONWO9912896
DESCRIPTIONWO9912898
DESCRIPTIONWO9925358
DESCRIPTIONWO9926629
DESCRIPTIONWO9932441
OPPOSITIONEP1541151
OPPOSITIONJP2009298808
OPPOSITIONJP2013035802
OPPOSITIONJP2014019650
OPPOSITIONWO2004019951
OPPOSITIONWO2008105058
OPPOSITIONWO2010011853
OPPOSITIONWO2010126626
OPPOSITIONWO2010127329
OPPOSITIONWO2012105674
SEARCHEP1541151
SEARCHEP2671586
SEARCHWO2010011853
SEARCHWO2010127329
SEARCHWO2012105674

Non-Patent Literature (NPL) Citations (27) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
DESCRIPTION- BERGE et al., "Pharmaceutically Acceptable Salts", J. Pharm. Sci., (19770000), vol. 66, pages 1 - 19
DESCRIPTION- C. LILJEBRIS; G. SELEN; B. RESUL; J. STERNSCHANTZ; U. HACKSELL, "Derivatives of 17-Phenyl-18,19,20-trinorprostaglandin F Isopropyl Ester: Potential Anti-glaucoma Agents", Journal of Medicinal Chemistry, (19950000), vol. 38, no. 2, pages 289 - 304
DESCRIPTION- C.T.F.A. Cosmetic Ingredient Handbook, (19920000), pages 587 - 592
DESCRIPTION- "North American Edition", McCutcheon's Volume 1, Emulsifiers & Detergents, (19940000), vol. 1, pages 236 - 239
DESCRIPTION- Remington's Pharmaceutical Sciences, (19750000), pages 335 - 337
DESCRIPTION- Remington's Pharmaceutical Sciences, Meade Publishing Co.
OPPOSITION- Anonymous, "Aerie Pharmaceuticals, Inc. Gets Good News on Glaucoma Treatment", page 1, URL: http://www.biospace.com, (20140603), XP002725385
OPPOSITION- Anonymous, "Chapter 76", Remington's Pharmaceutical Sciences, (19850101), pages 1418 - 1419, XP055639960
OPPOSITION- Anonymous, "Kowa Announces the Efficacy and Safety of a Novel Rho Kinase Inhibitor (K-115) in the Treatment of Glaucoma", Press release KOWA, (20110509), pages 1 - 4, XP055839491
OPPOSITION- Bito Lazlo Z, "A physiological approach to glaucoma management: the use of local hormones and the pharmacokinetics of prostaglandin esters.", Progress in Clinical and Biological ResearchProgress in Clinical and Biological Research, Liss, (19890101), pages 329 - 347, XP055839481
OPPOSITION- C. Hahmann ; T. Schroeter, "Rho-kinase inhibitors as therapeutics: from pan inhibition to isoform selectivity", Cellular and Molecular Life Sciences, Birkhäuser-Verlag, Ba, Ba, (20091112), vol. 67, no. 2, ISSN 1420-9071, pages 171 - 177, XP019777008
OPPOSITION- Helzner Gerald, Et Al, "Ophthalmology Management - Bright New Ideas In Glaucoma Treatment", Ophthalmology management, (20130101), pages 1 - 6, Ophthalmology management, URL: https://www.ophthalmologymanagement.com/issues/2013/january-2013/bright-new-ideas-in-glaucoma-treatment, (20210909), XP055839420
OPPOSITION- H. SONG et al., "Fasudil, a Rho-associated protein kinase inhibitor, attenuates retinal ischemia and reperfusion injury in rats", International Journal of Molecular Medicine, (20110000), vol. 28, pages 193 - 198, XP009189261
OPPOSITION- Kumar L; Amin A; Bansal A K, "Salt selection in drug development", Pharmaceutical Technology, ADVANSTAR COMMUNICATIONS,INC., US, US, (20080301), vol. 32, no. 3, ISSN 1543-2521, pages 128 - 146, XP008127365
OPPOSITION- Mitchell A. deLong et al, "Discovery and SAR of a Class of Ocularly-active Compounds Displaying a Dual Mechanism of Activity for the Treatment of Glaucoma", ARVO Annual Meeting, May 6 - 10 2012, Fort Lauderdale, FL, (20120506), page 1, XP002725387
OPPOSITION- Mizuno Ken, Et Al, "Ocular Hypotensive Mechanism Of K-115, A Rho-kinase Inhibitor, And Rho-kinase Expression In The Eye | IOVS | ARVO Journals", ARVO annual meeting abstract, (20110401), pages 237 - 238, ARVO annual meeting abstract, URL: https://iovs.arvojournals.org/article.aspx?articleid=2349759, (20210909), XP055839453
OPPOSITION- Robin Alan L, "Aerie Pharmaceuticals Announces Positive Phase 2a Clinical Results for its Novel, Dual Mechanism Compound, AR-13324, for the Treatment of Glaucoma", AERIE, (20121101), pages 1 - 3, AERIE, URL: https://investors.aeriepharma.com/static-files/873eda80-d00c-420b-8560-e873b02cdf6c, (20210909), XP055839470
OPPOSITION- Wermuth Camille G, Et Al, "Introduction", Handbook of Pharmaceutical Salts, Wiley, (20020101), pages 1 - 7, XP055839436
OPPOSITION- Yu A, Et Al, "Wirkmechanismen, klinisches Profil und Stellenwert von Prostaglandin- und Prostamid-Analoga in der antiglaukomatösen Therapie", Klinische Monatsblätter für Augenheilkunde, (20130101), vol. 230, pages 127 - 132, XP055839488
OPPOSITION- Amano Mutsuki, Nakayama Masanori, Kaibuchi Kozo, "Rho-kinase/ROCK: A key regulator of the cytoskeleton and cell polarity", Cytoskeleton (Hoboken, N.J.), John Wiley & Sons, Inc, Hoboken, USA, Hoboken, USA, doi:10.1002/cm.20472, (20100901), pages 545 - 554, Cytoskeleton (Hoboken, N.J.), URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3038199/pdf/cm0067-0545.pdf, (20210909), XP055839462
OPPOSITION- ELDER et al., "The Utility of Sulfonate Salts in Drug Development", Journal of Pharmaceutical Sciences, (20100000), vol. 99, doi:10.1002/jps.22058, pages 2948 - 2961, XP055091305
OPPOSITION- BERGE et al., "Pharmaceutical Salts", Journal of Pharmaceutical Sciences, (19770100), vol. 66, no. 1, doi:10.1002/jps.2600660104, pages 1 - 19, XP002675560
OPPOSITION- Fogagnolo Paolo, Rossetti Luca, "Medical treatment of glaucoma: present and future", Expert Opinion on Investigational Drugs, Informa Healthcare, UK, UK, (20110701), vol. 20, no. 7, doi:10.1517/13543784.2011.579901, ISSN 1354-3784, pages 947 - 959, XP055839441
OPPOSITION- Colligris Basilio, Crooke Almudena, Huete Fernando, Pintor Jesus, "Potential Role of Rho-Associated Protein Kinase Inhibitors for Glaucoma Treatment", Recent Patents on Endocrine, Metabolic and Immune Drug Discovery, (20120501), vol. 6, no. 2, doi:10.2174/187221412800604554, ISSN 1872-2148, pages 89 - 98, XP055839446
SEARCH- Anonymous, "Aerie Pharmaceuticals, Inc. Gets Good News on Glaucoma Treatment", (20120211), Internet, URL: http://www.biospace.com, (20140603), XP002725385 [Y] 1-6 * 4th paragraph *
SEARCH- Anonymous, "Bright New Ideas in Glaucoma Treatment", (201301), Internet, URL: http://mydigimag.rrd.com, (20140603), XP002725386 [Y] 1-6 * page 1, paragraph 5 *
SEARCH- Anonymous, "Discovery and SAR of a Class of Ocularly-active Compounds Displaying a Dual Mechanism of Activity for the Treatment of Glaucoma", ARVO Annual Meeting, May 6 - 10 2012, Fort Lauderdale, FL, (20120506), Internet, URL: http://www.aeriepharma.com, (20140603), XP002725387 [A] 1-6 * abstract *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents